InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled “Global Mechanical Thrombectomy Devices Market by (Product Type (Coil Retriever Devices, Stent Retriever Devices, Aspiration Devices, Manual Thrombectomy Devices, And Others (Ultrasound-Based Devices)), Application Type (Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arteriovenous Fistula (AVF), Peripheral Arterial Disease (PAD), Hemodialysis Treatments, Percutaneous Coronary Intervention (PCI), And Others), End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, And Academic & Research Institutes)) – Market Outlook and Industry Analysis 2030” According to company’s newest research, the global Mechanical Thrombectomy Devices Market is worth US$ 1.26 Billion in 2021 and is predicted to reach US$ 2.27 Billion in 2030, with a promising CAGR of 6.9 % between 2022 and 2030.
Get Demo Sample copy of Mechanical Thrombectomy Devices Market Report at: https://www.insightaceanalytic.com/request-sample/1212
Mechanical thrombectomy is a viable alternative to standard stroke treatments today. Mechanical thrombectomy devices are a group of endovascular instruments that have been cleared for eliminating thrombi from the neurovasculature in patients with acute ischemic stroke. The capacity to offer site-specific therapy, adjusted thrombolytic dosage and delivery, extended treatment time windows, and improved recanalization rates all seem to be potential benefits. It can also be utilized as rescue therapy in patients who haven’t responded to IV rtPA or as part of a treatment plan that includes other endovascular procedures.
Mechanical thrombectomy is now a standard treatment for stroke caused by a major artery blockage. Stroke is the world’s second-largest cause of mortality and the top cause of disability. According to the World Health Organization, 17.9 million people die each year from cardiovascular disorders (CVDs). Heart attacks and strokes account for over 85% of CVD mortality. In the coming years, the demand for mechanical thrombectomy devices is expected to rise as the world’s population ages, resulting in an increase in the incidence of cardiovascular diseases. Rising demand for minimally invasive procedures, hospitals’ rapid adoption of new devices, and improved healthcare infrastructure are further driving the market.
The mechanical thrombectomy devices market was dominated by the North American region. The increasing number of ischemic stroke cases, the presence of prominent companies, and the growing demand for minimally invasive solutions are factors that contribute to regional growth. Moreover, increasing cardiovascular disease, rising healthcare costs, and technical improvements in devices are expected to drive Asia-market Pacific’s growth during the forecast period.
For more Customization in this Report, Connect with us at: https://www.insightaceanalytic.com/customisation/1212
- In March 2022, India Medtronic Private Limited, a wholly-owned subsidiary of Medtronic plc, announced the establishment of India’s first dedicated registry for the collection of real-world data on the use of revascularization devices in patients suffering from acute ischemic stroke (AIS).
- In Feb 2022, Imperative Care Inc. announced the introduction of Zoom POD Aspiration Tubing, the company’s latest advancement in stroke care. The Zoom POD is the newest addition to Imperative Care’s Zoom Stroke Solution, which also comprises the Zoom 88 Large Distal Platform for neurovascular access, four Zoom Aspiration Catheters in a variety of diameters, and the Zoom Pump with accessories.
- In June 2021, Penumbra, Inc. announced the 510(k) clearance and commercial availability of the REDTM 62 Reperfusion Catheter from the United States Food and Drug Administration (FDA). The REDTM 62 Reperfusion Catheter is the latest addition to the company’s entire Penumbra System®. Together with Penumbra ENGINE®, the RED 62 is designed to navigate complex distal artery anatomy and deliver forceful aspiration for the removal of blood clots in acute ischemic stroke patients with big arterial occlusions.
- In June 2021, Boston Scientific Corporation announced the acquisition of Devoro Medical, Inc., creators of the WOLF Thrombectomy® Platform. The novel, non-console, and lytic-free WOLF technology rapidly target and collects blood clots with finger-like prongs that retrieve and remove thrombi in the arterial and venous systems.
The following key companies are engaged in the Mechanical Thrombectomy Devices market:
Animal Biome, Inc., ANIZOME LLC, Cargill, Chr. Hansen Holding A/S, Cytophage Technologies Inc., DuPont Industrial Biosciences, Elanco Animal Health, EnBiotix, Inc., Gnubiotics Sciences SA, Hill’s Pet Nutrition, Inc., Intralytix, Koninklijke DSM N.V. (Royal DSM), Lallemand Inc., Land O’Lakes, Inc., Leiber GmbH, MicroSintesis, NomNomNow Inc., Novozymes A/S, Orion Pharma Animal Health, Phage Technologies SA, Phagelux, Inc., Phibro Animal Health Corporation, ProDigest, Tonicity International Limited, and VetoPhage.
Get Extra Discount on Mechanical Thrombectomy Devices Market Report, if your Company is Listed in Above Key Players List @ https://www.insightaceanalytic.com/enquiry-before-buying/1212